It is very uncertain whether adjuvant chemotherapy changes all‐cause mortality at 5 years compared with no chemotherapy (very low certainty).
It is very uncertain whether external beam radiotherapy (EBRT) changes all‐cause mortality (at 1 year) compared with transarterial chemoembolisation (TACE) (very low certainty).
External beam radiotherapy (EBRT) plus transarterial… may leads to lower all‐cause mortality (at maximum 1‐year compared with TACE alone (low certainty).
It is very uncertain whether gemcitabine plus oxaliplatin changes all‐cause mortality at 1 year compared with 5‐fluorouracil plus cisplatin plus radiotherapy (very low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
It is very uncertain whether gemcitabine plus cisplatin changes all‐cause mortality at 1 year compared with S‐1 plus cisplatin (very low certainty).
It is very uncertain whether gemcitabine plus S‐1 changes all‐cause mortality at 1 year compared with S‐1 (very low certainty).
It is very uncertain whether gemcitabine plus oxaliplatin changes all‐cause mortality at 1 year compared with best supportive care (very low certainty).
It is very uncertain whether gemcitabine plus oxaliplatin changes all‐cause mortality at 1 year compared with 5‐fluorouracil plus folinic acid (very low certainty).
It is very uncertain whether gemcitabine plus mitomycin C changes all‐cause mortality at 1 year compared with capecitabine plus mitomycin C (very low certainty).
The review found no eligible studies for this question.
TACE followed by 3‐DCRT may leads to lower all‐cause mortality: at 3 years compared with TACE (low certainty).
It is very uncertain whether adjuvant S‐1 changes all‐cause mortality: 1‐year overall survival compared with gemcitabine (very low certainty).
It is very uncertain whether adjuvant S‐1 changes all‐cause mortality: 2‐year overall survival compared with gemcitabine (very low certainty).